posted on 2023-04-04, 01:45authored byRyan M. Murphy, Jason Tasoulas, Alessandro Porrello, Miranda B. Carper, Yi-Hsuan Tsai, Alisha R. Coffey, Sunil Kumar, Peter YF. Zeng, Travis P. Schrank, Bentley R. Midkiff, Stephanie Cohen, Ashley H. Salazar, Michele C. Hayward, D. Neil Hayes, Andrew Olshan, Gaorav P. Gupta, Anthony C. Nichols, Wendell G. Yarbrough, Chad V. Pecot, Antonio L. Amelio
Crude 5- and 10-year survival rates by p16 cytoplasmic/nuclear status.
Funding
HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
HHS | NIH | National Cancer Institute (NCI)
HHS | NIH | National Institute of General Medical Sciences (NIGMS)
CIHR Vanier Canada Graduate Scholarship
PSI Foundation Fellowship
Wolfe Surgical Research Professorship in the Biology of Head and Neck Cancers Fund
University Cancer Research Fund
UNC Lineberger Tier 3 Developmental Award
Lung Cancer Research Foundation (LCRF)
Free To Breathe (FtB)
North Carolina Biotechnology Translation Research Grant
History
ARTICLE ABSTRACT
These findings indicate that codetection of SYNGR3 in immune cells and p16 in tumor cells by IHC can more reliably identify the HPV(+) subgroup of patients with low-risk head and neck cancer that may be appropriate for clinical trials involving treatment deescalation.